Biogen (BIIB) Market Cap (1999 - 2026)
Biogen (BIIB) market cap from Nov 1, 1999 to Jun 2, 2026. The current Biogen (BIIB) market cap is $28B. You can adjust inflation or export chart.
All data is split-adjusted. You can find the most accurate data from the reports on the SEC official website. We recommend verify information using official company filings before making investment decisions.
Market Cap
Biogen (BIIB) Market Cap CAGR table
| Period | CAGR |
|---|---|
| 1 Year TTM | -2.90% |
| 3 Years TTM | -14.09% |
| 5 Years TTM | -11.09% |
| 10 Years TTM | -10.18% |
| All Time TTM | +5.84% |
Annual Market Cap change of Biogen (BIIB)
| Year | Market Cap | Change |
|---|---|---|
| 2026 | $28B | +7.74% |
| 2025 | $26B | +15.80% |
| 2024 | $22B | -40.54% |
| 2023 | $37B | -6.30% |
| 2022 | $40B | +12.61% |
| 2021 | $36B | -7.58% |
| 2020 | $38B | -31.96% |
| 2019 | $56B | -9.17% |
| 2018 | $62B | -8.38% |
| 2017 | $68B | +9.26% |
| 2016 | $62B | -13.42% |
| 2015 | $72B | -10.71% |
| 2014 | $80B | +21.20% |
| 2013 | $66B | +91.49% |
| 2012 | $35B | +29.49% |
| 2011 | $27B | +66.20% |
| 2010 | $16B | +4.05% |
| 2009 | $15B | +120.46% |
| 2008 | $7.01B | -16.32% |
| 2007 | $8.38B | +15.71% |
| 2006 | $7.24B | +8.64% |
| 2005 | $6.67B | -32.02% |
| 2004 | $9.80B | +81.50% |
| 2003 | $5.40B | +10.64% |
| 2002 | $4.88B | -51.88% |
| 2001 | $10B | +9.09% |
| 2000 | $9.30B | +92.94% |
| 1999 | $4.82B | N/A |
Comparison Biogen (BIIB) market cap with competitors
Biogen (BIIB) market cap is $27.80B.
| Ticker | Name | Market Cap | Upside |
|---|---|---|---|
| LLY | Lilly(Eli) & Company | $969.83B | +3389.14% |
| JNJ | Johnson & Johnson | $557.13B | +1904.38% |
| ABBV | Abbvie Inc | $381.28B | +1271.70% |
| MRK | Merck & Co Inc | $297.23B | +969.35% |
| AZN | Astrazeneca plc | $289.83B | +942.72% |
| NVS | Novartis AG | $289.55B | +941.69% |
| NVO | Novo Nordisk | $198.19B | +613.02% |
| AMGN | AMGEN Inc | $181.37B | +552.51% |
| GILD | Gilead Sciences Inc | $166.04B | +497.37% |
| PFE | Pfizer Inc | $149.16B | +436.63% |
| BMY | Bristol-Myers Squibb Company | $117.25B | +321.81% |
| SNY | Sanofi | $107.01B | +284.97% |
| GSK | GSK Plc | $105.07B | +278.00% |
| GRFS | Grifols SA | $5.48B | -80.29% |
| OGN | Organon & Company | $3.51B | -87.36% |
| AMRN | Amarin Corp | $304.63M | -98.90% |
| SCLX | Scilex Holding Company | $57.83M | -99.79% |
| MIRA | Mira Pharmaceuticals Inc | $48.54M | -99.83% |
| NSRX | Nasus Pharma Ltd | $27.23M | -99.90% |
| MDCXW | Medicus Pharma Ltd warrant | $14.00M | -99.95% |
| MDCX | MDCorp | $12.34M | -99.96% |